Durable Clinical Effectiveness with Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial

Keyphrases

• Clinical Efficacy 100%
• Randomized Trial 100%
• Popliteal Artery 100%
• Drug-eluting Stent 100%
• 5-year Outcomes 100%
• Paclitaxel-eluting Stent 100%
• Zilver PTX 100%
• Percutaneous Transluminal Angioplasty 50%
• Bare Metal Stent 40%
• Endovascular Treatment 20%
• Femoropopliteal Disease 20%
• Comparison with a Standard 20%
• Paclitaxel 10%
• Ischemia 10%
• Restenosis 10%
• Randomized Controlled Trial 10%
• Claudication 10%
• Critical Limb Ischemia 10%
• Event-free Survival 10%
• Clinical Benefit 10%
• Patency 10%
• Arterial Lesions 10%
• Unique Identifier 10%
• Clinical Trial Registry 10%
• Relative Risk Reduction 10%
• Long-term Information 10%
• Target Lesion Revascularization 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Paclitaxel 100%
• Artery Disease 100%
• Symptom 50%
• Clinical Trial 50%
• Ischemia 50%
• Randomized Controlled Trial 50%
• Restenosis 50%
• Event Free Survival 50%
• Claudication 50%
• Critical Limb Ischemia 50%
• Artery Lesion 50%

Medicine and Dentistry

• Paclitaxel 100%
• Artery 100%
• Drug-Eluting Stent 100%
• Percutaneous Transluminal Angioplasty 50%
• Artery Disease 20%
• Symptom 10%
• Ischemia 10%
• Clinical Trial 10%
• Restenosis 10%
• Randomized Controlled Trial 10%
• Artery Lesion 10%
• Critical Limb Ischemia 10%
• Claudication 10%
• Event Free Survival 10%
• Relative Risk Reduction 10%
• Target Lesion Revascularization 10%